{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T04:29:17Z","timestamp":1783225757105,"version":"3.54.6"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Illicit drug use increases visits to the hospital. Research is limited on the costs of these healthcare visits by illicit drug.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Florida\u2019s Agency for Health Care Administration\u2019s emergency department and inpatient datasets from 2016 to 2018 were analyzed. Adults who used an illicit drug were included in the study population resulting in 709,658 observations. Cost-to-charge ratios were used to estimate healthcare costs. Linear regression analyzed associations of illicit drugs with total healthcare cost.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Total healthcare costs are estimated at $6.4 billion over the 3 year period. Medicare paid for the most patient care ($2.16 billion) with Medicaid and commercial insurance each estimated at $1.36 billion. Cocaine (9.25%) and multiple drug use (6.12%) increased the costs of an ED visit compared to a patient with cannabis SUD. Opioids (23.40%) and inhalants use (16.30%) increased the costs of inpatient compared to cannabis SUD.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Healthcare costs are high of patients with illicit drug SUD and poisoning, over half of which are paid for with tax payer dollars and to an unknown degree hospital write-offs. Injuries and illness of patients using cocaine and multiple drugs are associated with more expensive ED patient care and opioids and inhalants are associated with more expensive inpatient care.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13011-020-00313-2","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T11:03:09Z","timestamp":1601377389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Healthcare cost associations of patients who use illicit drugs in Florida: a retrospective analysis"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5251-7501","authenticated-orcid":false,"given":"Jessica L.","family":"Ryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica R.","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"issue":"3","key":"313_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0193841X12450164","volume":"36","author":"PK Alexandre","year":"2012","unstructured":"Alexandre PK, Beulaygue IC, French MT, McCollister KE, Popovici I, Sayed BA. The economic cost of substance abuse treatment in the state of Florida. Eval Rev. 2012;36(3):167\u201385.","journal-title":"Eval Rev"},{"issue":"4","key":"313_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1526-4637.2011.01075.x","volume":"12","author":"HG Birnbaum","year":"2011","unstructured":"Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657\u201367.","journal-title":"Pain Med"},{"key":"313_CR3","volume-title":"Epicenter Alcohol\/Drug Consequences Query: Categories and ICD Codes Used","author":"California Department of Public Health","year":"2014","unstructured":"California Department of Public Health. Epicenter Alcohol\/Drug Consequences Query: Categories and ICD Codes Used. 2014. https:\/\/www.cdph.ca.gov\/Programs\/CCDPHP\/DCDIC\/SACB\/CDPH%20Document%20Library\/EpiCenter\/AOD-ICD-Coding-070315.pdf. Accessed 4 Feb 2020."},{"key":"313_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jsat.2015.05.001","volume":"57","author":"RE Clark","year":"2015","unstructured":"Clark RE, Baxter JD, Aweh G, O\u2019Connell E, Fisher WH, Barton BA. Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abus Treat. 2015;57:75\u201380.","journal-title":"J Subst Abus Treat"},{"key":"313_CR5","doi-asserted-by":"publisher","unstructured":"Fairman BJ, Hwang S, Alexandre PK, Gallo JJ, Eaton WW. Costs of substance use disorders from claims data for Medicare recipients from a population-based sample. J Subst Abus Treat. 2017. https:\/\/doi.org\/10.1016\/j.jsat.2017.02.007.","DOI":"10.1016\/j.jsat.2017.02.007"},{"key":"313_CR6","doi-asserted-by":"publisher","unstructured":"Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016. https:\/\/doi.org\/10.1097\/MLR.0000000000000625.","DOI":"10.1097\/MLR.0000000000000625"},{"key":"313_CR7","doi-asserted-by":"publisher","unstructured":"Graham K, Cheng J, Bernards S, Wells S, Rehm J, Kurdyak P. How much do mental health and substance use\/addiction affect use of general medical services? Extent of use, reason for use, and associated costs. Can J Psychiatr. 2017. https:\/\/doi.org\/10.1177\/0706743716664884.","DOI":"10.1177\/0706743716664884"},{"issue":"1","key":"313_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1377\/hlthaff.2015.0618","volume":"35","author":"J Gryczynski","year":"2016","unstructured":"Gryczynski J, Schwartz RP, O\u2019Grady KE, Restivo L, Mitchell SG, Jaffe JH. Understanding patterns of high-cost health care use across different substance user groups. Health Aff. 2016;35(1):12\u20139.","journal-title":"Health Aff"},{"issue":"9","key":"313_CR9","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1111\/add.13795","volume":"112","author":"DJ Hsu","year":"2017","unstructured":"Hsu DJ, McCarthy EP, Stevens JP, Mukamal KJ. Hospitalizations, costs and outcomes associated with heroin and prescription opioid overdoses in the United States 2001-12. Addiction. 2017;112(9):1558\u201364.","journal-title":"Addiction."},{"key":"313_CR10","doi-asserted-by":"publisher","unstructured":"Jakovljevic MB, Jovanovic M, Lesch OM. Accessiblity and affordability of alcohol dependency medical care in Serbia. Front Psychiatry. 2014. https:\/\/doi.org\/10.3389\/fpsyt.2014.00192.","DOI":"10.3389\/fpsyt.2014.00192"},{"key":"313_CR11","doi-asserted-by":"publisher","unstructured":"Kamal R, Cox C, Rousseau D. Costs and outcomes of mental health and substance use disorders in the US. JAMA. 2017. https:\/\/doi.org\/10.1001\/jama.2017.8558.","DOI":"10.1001\/jama.2017.8558"},{"issue":"7","key":"313_CR12","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/pme.12768","volume":"16","author":"NY Kirson","year":"2015","unstructured":"Kirson NY, Shei A, Rice JB, Enloe CJ, Bodnar K, Birnbaum HG, et al. The burden of undiagnosed opioid abuse among commercially insured individuals. Pain Med. 2015;16(7):1325\u201332.","journal-title":"Pain Med"},{"key":"313_CR13","doi-asserted-by":"publisher","first-page":"S716","DOI":"10.2105\/AJPH.2015.302693","volume":"105","author":"W Lin","year":"2015","unstructured":"Lin W, Bharel M, Zhang J, O\u2019Connell E, Clark RE. Frequent emergency department visits and hospitalizations among homeless people with Medicaid: implications for Medicaid expansion. Am J Public Health. 2015;105:S716\u201322.","journal-title":"Am J Public Health"},{"key":"313_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/SAR.S135884","volume":"8","author":"DD Maeng","year":"2017","unstructured":"Maeng DD, Han JJ, Fitzpatrick MH, Boscarino JA. Patterns of health care utilization and cost before and after opioid overdose: findings from 10-year longitudinal health plan claims data. Subst Abus Rehabil. 2017;8:57.","journal-title":"Subst Abus Rehabil"},{"key":"313_CR15","doi-asserted-by":"publisher","unstructured":"Martins SS, Sampson L, Cerda M, Galea S. Worldwide prevalence and trends in unintentional drug overdose: a systematic review of the literature. Am J Public Health. 2015. https:\/\/doi.org\/10.2105\/AJPH.2015.302843.","DOI":"10.2105\/AJPH.2015.302843"},{"issue":"4","key":"313_CR16","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/acer.13337","volume":"41","author":"TR Miller","year":"2017","unstructured":"Miller TR, Nygaard P, Gaidus A, Grube JW, Ponicki WR, Lawrence BA, et al. Heterogeneous costs of alcohol and drug problems across cities and counties in California. Alcohol Clin Exp Res. 2017;41(4):758\u201368.","journal-title":"Alcohol Clin Exp Res"},{"key":"313_CR17","volume-title":"ICD-10 mental health billable diagnosis codes in alphabetical order by description","author":"Minnesota Department of Human Services","year":"2017","unstructured":"Minnesota Department of Human Services. ICD-10 mental health billable diagnosis codes in alphabetical order by description. 2017. https:\/\/www.dhs.state.mn.us\/main\/groups\/agencywide\/documents\/pub\/dhs16_197744.pdf. Accessed 5 Feb 2020.."},{"key":"313_CR18","unstructured":"National Survey of Drug Use and Health. National Institute on Drug Abuse (NIDA)a. 2020. https:\/\/www.drugabuse.gov\/drug-topics\/trends-statistics\/national-drug-early-warning-system-ndews\/national-survey-drug-use-health. Accessed 3 Apr 2020."},{"key":"313_CR19","unstructured":"Drug Abuse Trends and Statistics. NIDAb. 2020. https:\/\/www.drugabuse.gov\/drug-topics\/trends-statistics#supplemental-references-for-economic-costs. Accessed 3 Apr 2020."},{"issue":"9","key":"313_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.24095\/hpcdp.38.9.04","volume":"38","author":"MC Otterstatter","year":"2018","unstructured":"Otterstatter MC, Crabtree A, Dbrer S, Kinniburgh B, Klar S, Leamon A, et al. Patterns of health care utilization among people who overdosed from illegal drugs: a descriptive analysis using the BC provincial overdose cohort. Health Promot Chron. 2018;38(9):328\u201333.","journal-title":"Health Promot Chron"},{"issue":"1","key":"313_CR21","first-page":"18","volume":"117","author":"BL Rooney","year":"2018","unstructured":"Rooney BL, Voter MT, Eberlein CM, Schossow AJ, Fischer CL. Mapping drug overdose demographic and socioeconomic characteristics in the community. WMJ. 2018;117(1):18\u201323.","journal-title":"WMJ."},{"key":"313_CR22","first-page":"227","volume":"1","author":"JD Ropero-Miller","year":"2019","unstructured":"Ropero-Miller JD, Speaker PJ. The hidden costs of the opioid crisis and the implications for financial management in the public sector. Forensic Sci Int: Synergy. 2019;1:227\u201338.","journal-title":"Forensic Sci Int: Synergy"},{"key":"313_CR23","doi-asserted-by":"publisher","unstructured":"Rosenberg L. Surgeon General\u2019s report on addiction: what does it mean? J Behav Health Ser R. 2017. https:\/\/doi.org\/10.1007\/s11414-016-9544-5.","DOI":"10.1007\/s11414-016-9544-5"},{"issue":"1","key":"313_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2105\/AJPH.2008.149534","volume":"100","author":"L Schonfeld","year":"2010","unstructured":"Schonfeld L, King-Kallimanis BL, Duchene DM, Etheridge RL, Herrara JR, Barry KL, et al. Screening and brief intervention of substance misuse among older adults: The Florida BRITE project. Am J Public Health. 2010;100(1):108\u201314.","journal-title":"Am J Public Health"},{"key":"313_CR25","volume-title":"Common comorbidities","author":"Substance Abuse and Mental Health Services Administration","year":"2019","unstructured":"Substance Abuse and Mental Health Services Administration. Common comorbidities 2019. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/treatment\/common-comorbidities. Accessed 5 Feb 2020."},{"key":"313_CR26","volume-title":"Research on health care costs of untreated conditions is limited. GAO-19-274","author":"United States Government Accountability Office","year":"2019","unstructured":"United States Government Accountability Office. Research on health care costs of untreated conditions is limited. GAO-19-274. 2019."},{"key":"313_CR27","first-page":"e59","volume":"3","author":"AG White","year":"2011","unstructured":"White AG, Birnbaum HG, Schiller M, Waldman T, Cleveland JM, Roland CL. Economic impact of opioid abuse, dependence, and misuse. AM J Pharm Benefits. 2011;3:e59\u201370.","journal-title":"AM J Pharm Benefits"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-020-00313-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-020-00313-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-020-00313-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T23:46:59Z","timestamp":1632872819000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-020-00313-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["313"],"URL":"https:\/\/doi.org\/10.1186\/s13011-020-00313-2","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"20 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N\/A","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}